MediPharm Labs Posts Q3 Revenues of $5.4 Million, Continues To Post Negative Gross Margins

MediPharm Labs (TSX: LABS) this morning reported its third quarter financial results, posting revenues of $5.4 million for the quarter. The firm also posted a net loss of $7.4 million for the period.

Revenues were effectively flat for the the quarter, climbing from $5.1 million to $5.4 million on a quarter over quarter basis, while the firm still looks to improve upon its first quarter revenue figure of $5.5 million. Gross profit was again negative, a trend that has occurred all year, with the company posting a gross loss of $1.9 million.

Operating expenses further added to the losses, with general administrative expenses coming in at $4.6 million followed by marketing and selling expenses of $0.9 million. The firm overall posted an operating loss of $7.5 million, which resulted in a net loss of $7.5 million after a small $0.1 million income tax recovery.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Adjusted EBITDA meanwhile amounted to a loss of $5.6 million.

The firm also noted that its new CEO, Bryan Howcroft, is expected to start today, which is expected to improve international and pharmaceutical sales growth.

MediPharm Labs last traded at $0.315 on the TSX.


.Information for this briefing was found via Sedar and Medipharm Labs. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Harvest Moon: Valens Company VS Medipharm Labs – Share Price Indicators

Of the 100 companies in the BI Global Cannabis Competitive Peers index tracked in 2019,...

Sunday, June 21, 2020, 05:00:00 PM

Medipharm Labs Closes $33.4 Million Bought Deal Financing

Medipharm Labs (TSX: LABS) has closed the bought deal financing that it announced and then...

Friday, March 5, 2021, 09:12:09 AM

Medipharm Labs Increases Bought Deal To $29.0 Million

Medipharm Labs (TSX: LABS) has increased the size of the bought deal financing announced last...

Tuesday, March 2, 2021, 09:26:39 AM

Medipharm Labs and Cronos Group Sign Second Manufacturing Agreement

Medipharm Labs (TSX: LABS) and Cronos Group (TSX: CRON) (NASDAQ: CRON) have entered into their...

Thursday, September 19, 2019, 09:23:17 AM

Medipharm Signs Danish White Label Agreement

Medipharm Labs (TSX: LABS) continues to expand its international presence, this morning announcing that it...

Friday, September 25, 2020, 08:49:28 AM